資料搜尋諮詢服務
找不到您所需要的資料嗎?
我們能協助您找到最符合您研究需求的資訊
請撥打 +886-2-2799-3110
或透過電子郵件與我們聯絡 mi@hintoninfo.com
IHS_EWBIEEE xploreSTRATEGY ANALYTICSELSEVIERIHS_EWB_GF

頁面路徑選單

最新消息http://www.hintoninfo.com.tw/

2020/04/09 Coronavirus Disease (COVID-19): Epidemiology Analysis and Forecast – March 2020

 High-Risk Group Analysis: Diabetes, Heart Disease, and Rare Diseases

Coronavirus Disease (COVID-19): Epidemiology Analysis and Forecast - March 2020

The global CFR is 4.3%. In the 5MM, the highest case fatality rate occurs among the 80 years and older age group. In the 5MM (except Spain), the highest proportion of deaths occurs among the 80 years and older age group. 


Single User License: $1,995

Report format: PPT

First reported in Wuhan, China, in December 2019, now more than 846,200 confirmed cases of COVID-19 are spread across 180 countries worldwide. China had appeared to gain control of COVID-19. The US is now the most heavily affected country worldwide. Forecasts expect further rise in cases from the US and other countries across Europe. Italy and Switzerland may begin to see flattening of the epidemiological curve.

People at risk for severe COVID-19 include population with underlying health problems, such as respiratory disease, cardiovascular disease, cancer, diabetes, and some rare diseases. Populations aged 50 years of age and older are also more likely to have comorbidities and develop severe COVID-19, requiring hospitalization. There is no solid evidence to suggest that pregnant women are more at risk of COVID-19, but they are included in this category as a precaution.


The epidemiology analysis is limited by several data restrictions. Testing availability and criteria differ significantly among countries. All countries’ reported confirmed cases underestimate the number of actual infected people. And mortality reporting is not standardized.

Report Scope:

  • Global epidemiology metrics and trends - Snapshot of epidemiological trends to date in the top three most-affected countries
  • An overview of the pipeline for antivirals and vaccines
  • Summary of available efficacy data
  • An assessment of the clinical trials landscape by phase, sponsor type, geography, and other key attributes
  • Highlights in deal-making trends, particularly public-private partnerships
回上頁